^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    eribulin mesylate

    i
    Other names: E7389, ER-086526, B1939 mesylate, B-1939, Halichondrin B analog, NSC-707389
    Company:
    Generic mfg.
    Drug class:
    Microtubule inhibitor
    Related drugs:
    21h
    Scalp Cooling in MBC (clinicaltrials.gov)
    P2, N=120, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jun 2028 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • eribulin mesylate • Trodelvy (sacituzumab govitecan-hziy)
    1d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=1132, Recruiting, Hoffmann-La Roche | N=792 --> 1132
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • eribulin mesylate • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • giredestrant (RG6171) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    2d
    Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report. (PubMed, Anticancer Drugs)
    A 62-year-old man with metastatic PSA underwent splenectomy followed by first-line paclitaxel, achieving stable disease for 7 months...Sequential treatment with liposomal doxorubicin, eribulin, toripalimab, and lenvatinib failed to control the disease failed to control the disease...To our knowledge, this is the first reported use of inavolisib in angiosarcoma. The rapid biochemical and radiological response observed in this PIK3CA-mutated PSA supports early genomic profiling to identify actionable alterations and warrants prospective evaluation of combined phosphoinositide 3-kinase and vascular endothelial growth factor pathway inhibition in refractory angiosarcoma.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    paclitaxel • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • eribulin mesylate • Itovebi (inavolisib)
    7d
    The Evolving Landscape of Systemic Therapy for Liposarcoma. (PubMed, Cancers (Basel))
    Continued progress in biomarker-driven strategies and rational combination therapies is expected to further refine personalized treatment approaches and improve outcomes for patients with advanced liposarcoma.
    Review • Journal • IO biomarker
    |
    MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)
    |
    Xpovio (selinexor) • eribulin mesylate • Yondelis (trabectedin)
    9d
    Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer. (PubMed, Breast Cancer)
    Eribulin could help avoid the early deteriorations in QoL that occur during taxane therapy and maintain QoL for longer in patents with HER2-positive LABC/MBC receiving trastuzumab and pertuzumab.
    Journal • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • eribulin mesylate
    16d
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Trial primary completion date: Nov 2028 --> May 2031 | Trial completion date: Oct 2033 --> Apr 2036
    Trial completion date • Trial primary completion date
    |
    eribulin mesylate • zanzalintinib (XL092)
    22d
    Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study. (PubMed, Front Oncol)
    In this single-center retrospective exploratory analysis, eribulin-based therapy demonstrated preliminary activity in heavily pre-treated breast cancer patients with liver metastases. These hypothesis-generating findings warrant further prospective validation.
    Retrospective data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    eribulin mesylate
    23d
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027
    Trial completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • PTEN mutation
    |
    eribulin mesylate • Aliqopa (copanlisib)
    24d
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • eribulin mesylate • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • BNT326
    1m
    A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov)
    P3, N=644, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2028 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PD-L1 expression • PD-L1 negative
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • eribulin mesylate • Datroway (datopotamab deruxtecan-dlnk)
    1m
    Biomarkers in Spinal Metastasis of Breast Cancer: Insights Into Survival and Functional Outcomes. (PubMed, J Clin Neurol)
    Only ER expression was associated with the overall survival time when other confounding factors such as smoking status and treatment type were considered. A smoking history was associated with shorter survival, while eribulin was associated with survival prolongation.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Perjeta (pertuzumab) • capecitabine • eribulin mesylate